Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based T2 Biosystems has received a patent from US Patent and Trademark Office covering its T2Candida test.
Subscribe to our email newsletter
The patent describes the format and methodology of T2Candida test, desinged to detect and identify Candida species in a blood sample.
T2Candida will identify sepsis-causing Candida species directly from blood at ~1CFU/ml sensitivity in approximately three hours.
T2 Biosystems president and CEO John McDonough said that the highly sensitive and rapid T2MR technology will help identify Candida cells directly within a blood sample eliminating time-consuming and costly sample preparation.
"This piece of intellectual property adds further protection for T2 Bio’s breakthrough direct detection technology that we believe will have a profound impact on the diagnostic landscape for any molecular, immunoassay or hemostasis target," McDonough added.
T2 Bio has rights to over 20 worldwide patents, protecting several of the company’s assets, including its T2MR technology, T2Dx instrument and various applications of the technology.